Home LiteratureArticle Details
PMID: 7044592 Published · ppublish English Journal Article Review

The clinical pharmacology of VM26 and VP16-213. A brief overview.

Cancer chemotherapy and pharmacology ·Vol. 7 ·No. 2-3 ·1982-00-00 ·Pages 133-40

Creaven PJ

Abstract

暂无摘要

MeSH Terms
Biotransformation Blood-Brain Barrier Etoposide/metabolism Humans Intestinal Absorption Kinetics Models, Biological Podophyllotoxin/analogs & derivatives Teniposide/metabolism Tissue Distribution
Chemicals
Etoposide Teniposide Podophyllotoxin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Creaven P J
References (25)
25 references, click to expand
  1. PTG, a new antineoplastic epipodyphyllotoxin.
    Clin Pharmacol Ther. 1975 Aug;18(2):227-33 PMID: 1157447
  2. Podophyllotoxin derivative VP 16-213.
    Cancer Chemother Pharmacol. 1979;3(2):71-80 PMID: 389478
  3. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
    Cancer Chemother Rep. 1972 Dec;56(6):769-77 PMID: 4634038
  4. PHASE I clinical trial of an oral solution of VP-16-213.
    Cancer Treat Rep. 1976 Jul;60(7):943-5 PMID: 1009527
  5. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.
    Eur J Cancer. 1975 Oct;11(10):697-707 PMID: 1204664
  6. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cancer Treat Rep. 1978 Mar;62(3):473-5 PMID: 348319
  7. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.
    J Chromatogr. 1980 May 9;182(2):211-20 PMID: 7380913
  8. Etoposide (VP-16-213).
    Cancer Treat Rev. 1979 Jun;6(2):107-24 PMID: 385138
  9. The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26.
    Drug Metab Rev. 1978;8(1):119-35 PMID: 720213
  10. VM 26 and VP 16-213: a comparative analysis.
    Cancer. 1977 Jul;40(1):334-42 PMID: 328129
  11. EPEG, a new antineoplastic epipodophyllotoxin.
    Clin Pharmacol Ther. 1975 Aug;18(2):221-6 PMID: 1157446
  12. A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.
    Cancer. 1975 Apr;35(4):1141-4 PMID: 163675
  13. High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.
    J Chromatogr. 1981 Jan 2;222(1):141-5 PMID: 7217322
  14. Phase I trial of a new form of an oral administration of VP-16-213.
    Cancer Treat Rep. 1979 Mar;63(3):485-7 PMID: 371801
  15. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell.
    Cancer Res. 1978 Aug;38(8):2549-54 PMID: 667850
  16. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Cancer Treat Rep. 1979 Aug;63(8):1231-9 PMID: 225026
  17. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
    Cancer Chemother Rep. 1975 Sep-Oct;59(5):1027-9 PMID: 1106845
  18. Phase II study of VM-26 in adult malignancies.
    Cancer Treat Rep. 1980 Jan;64(1):147-9 PMID: 7379049
  19. Analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) by high-pressure liquid chromatography.
    J Pharm Sci. 1980 Dec;69(12):1440-1 PMID: 7463333
  20. Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.
    Cancer Treat Rep. 1976 Sep;60(9):1377-9 PMID: 1016971
  21. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Cancer Treat Rep. 1979 Jun;63(6):977-81 PMID: 380803
  22. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).
    Cancer Chemother Rep. 1974 Nov-Dec;58(6):901-7 PMID: 4615787
  23. 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review.
    Eur J Cancer. 1973 Jul;9(7):477-82 PMID: 4609765
  24. Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans.
    J Pharm Sci. 1978 Aug;67(8):1106-8 PMID: 671246
  25. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
    Cancer Chemother Rep. 1971 Dec;55(5):575-81 PMID: 4946082
Article Info
Journal
Cancer chemotherapy and pharmacology
Abbr.
Cancer Chemother Pharmacol
ISSN
0344-5704
DOI
10.1007/BF00254535
Published
1982-00-00
Pages
133-40
Language
English
Region
Germany
NLM ID
7806519
Subset
IM
External Links
PubMed source DOI: 10.1007/BF00254535 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2